Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461192 | 0.90 | PDE5A (1.00) | PDE5APDE2A | |
| SCHEMBL6779758 | 0.87 | PDE5A (0.85) | PDE5APDE2A | |
| SCHEMBL7904463 | 0.86 | PDE5A (0.85) | PDE5APDE2A | |
| Hydrochloric Acid SCHEMBL6595313 | 0.86 | PDE5A (1.00) | PDE5APDE2A | |
| SCHEMBL6780463 | 0.86 | PDE5A (0.86) | PDE5APDE2A | |
| Hydrochloric Acid SCHEMBL6590189 | 0.85 | PDE5A (1.00) | PDE5APDE2A | |
| Hydrochloric Acid SCHEMBL6778630 | 0.84 | PDE5A (0.84) | PDE5APDE2A | |
| SCHEMBL1962546 | 0.83 | PDE5A (1.00) | PDE5APDE2A | |
| Hydrochloric Acid SCHEMBL6598895 | 0.82 | PDE5A (1.00) | PDE5APDE2A | |
| Hydrochloric Acid SCHEMBL29801632 | 0.82 | PDE5A (1.00) | PDE5APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | PDE5A 2062/4885PDE2A 2204/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | PDE5A 2062/4885PDE2A 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.